Thimme, Robert 1970-
Robert Thimme researcher
VIAF ID: 10556851 (Personal)
Permalink: http://viaf.org/viaf/10556851
Preferred Forms
- 100 0 _ ‡a Robert Thimme ‡c researcher
- 100 1 _ ‡a Thimme, Robert ‡d 1970-
- 100 1 _ ‡a Thimme, Robert ‡d 1970-
4xx's: Alternate Name Forms (3)
5xx's: Related Names (3)
- 551 _ _ ‡a Berlin-Nikolassee ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 551 _ _ ‡a Freiburg im Breisgau ‡4 ortw ‡4 https://d-nb.info/standards/elementset/gnd#placeOfActivity
- 510 2 _ ‡a Universitätsklinikum Freiburg ‡b Klinik für Innere Medizin II ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
Adaptive subsets limit the anti-tumoral NK-cell activity in hepatocellular carcinoma | |
Bystander hyperactivation of preimmune CD8+ T cells in chronic HCV patients | |
Case series: convalescent plasma therapy for patients with COVID-19 and primary antibody deficiency | |
CD161+CD4+ T cells are enriched in the liver during chronic hepatitis and associated with co-secretion of IL-22 and IFN-γ | |
CD8-T-Zell-Differenzierung bei Patienten mit Common Variable Immunodeficiency | |
Charakterisierung adaptiver NK-Zellen bei der chronischen HBV- und HCV-Infektion | |
Chronic Hepatitis E in rheumatology and internal medicine patients : a retrospective multicenter European cohort study | |
Chronische Hepatitis-B-Virusinfektion: aktuelle und zukünftige Therapieansätze = Chronic hepatitis B virus infection: current and future treatment strategies | |
Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis | |
A comprehensive analysis of the impact of HIV on HCV immune responses and its association with liver disease progression in a unique plasma donor cohort | |
COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany | |
COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation | |
Decreased platelet aggregation in patients with decompensated liver cirrhosis and TIPS implantation | |
Effektivität und Sicherheit bei der endoskopischen Vollwandresektion von Adenokarzinomen mit dem FTRD® - System | |
Endoscopic full-thickness resection and its treatment alternatives in difficult-to-treat lesions of the lower gastrointestinal tract: a cost-effectiveness analysis | |
Endoscopic submucosal dissection of an esophageal granular cell tumor | |
Enolase represents a metabolic checkpoint controlling the differential exhaustion programmes of hepatitis virus-specific CD8+T cells | |
Evaluation of laboratory and sonographic parameters for detection of portal hypertension in patients with common variable immunodeficiency | |
Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma | |
Follicular T helper cell signatures in primary biliary cholangitis and primary sclerosing cholangitis | |
HCV-specific T cell responses during and after chronic HCV infection | |
Hepatitis B vaccine and NK cells: a new player in memory | |
Heterogeneity of HBV-specific CD8+ T-cell failure: implications for immunotherapy | |
High-dimensional profiling reveals Tc17 cell enrichment in active Crohn’s disease and identifies a potentially targetable signature | |
High-fructose diet alters intestinal microbial profile and correlates with early tumorigenesis in a mouse model of Barrett’s Esophagus | |
Immune escape pathways from the HBV core18-27 CD8 T cell response are driven by individual HLA class I alleles | |
Immune‐mediated pathology as a consequence of impaired immune reactions: the IMPATH paradox | |
Immunopathology caused by impaired CD8+ T‐cell responses | |
Immunpathogenese der Hepatitis-B- und C-Virus-Infektion | |
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study | |
Incidence and severity of immune-related hepatitis after dual checkpoint therapy is linked to younger age independent of herpes virus immunity | |
Inefficient induction of circulating TAA-specific CD8+ T-cell responses in hepatocellular carcinoma | |
Interferon lambda 4 impairs hepatitis C viral antigen presentation and attenuates T cell responses | |
Internal viral RNA sequences of the PB2 genome segment of influenza A virus are required for efficient generation of fully infectious particles | |
Management of portal, mesenteric vein thrombosis | |
Minimally trans-complementation-dependent HBV reporter vectors | |
Multimodal profiling reveals site-specific adaptation and tissue residency hallmarks of γδ T cells across organs in mice = Multimodal profiling reveals site-specific adaptation and tissue residency hallmarks of [gamma][delta] T cells across organs in mice | |
Mutational escape from cellular immunity in viral hepatitis: variations on a theme | |
Neoantigens as potential vaccines in hepatocellular carcinoma | |
Official congress report Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma Falk Symposium 199, Freiburg, october 14-15, 2015 | |
Outcome of antiviral immunity in the liver is shaped by the level of antigen expressed in infected hepatocytes : hepatology | |
Perspectives for novel therapeutic concepts in hepatocellular carcinoma targeting the stromal and innate immune microenvironment | |
Plasma cyclic guanosine monophosphate is a promising biomarker of clinically significant portal hypertension in patients with liver cirrhosis | |
Pre-existing immunity and vaccine history determine hemagglutinin-specific CD4 T cell and IgG response following seasonal influenza vaccination | |
Prognostic value of the CLIF‐C AD score in patients with implantation of transjugular intrahepatic portosystemic shunt | |
Prolonged SARS‐CoV‐2 shedding and mild course of COVID‐19 in a patient after recent heart transplantation | |
Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis | |
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine | |
Reduced mortality for over-the-scope clips (OTSC) versus surgery for refractory peptic ulcer bleeding: a retrospective study | |
Regulation der CD8+ T-Zellantwort durch OX40 in der chronischen HCV-Infektion | |
Role of immunity in pathogenesis and treatment of hepatocellular carcinoma | |
Role of immunomodulators in functional cure strategies for HBV | |
role of natural killer cells and CD8+ T cells in hepatitis b virus infection | |
Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial | |
SARS-CoV-2 and the liver: clinical and immunological features in chronic liver disease | |
SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals | |
SARS-CoV-2-specific T cell responses in immunocompromised individuals with cancer, HIV or solid organ transplants | |
Schutzwirkung des interferoninduzierten Mx1-Proteins der Maus gegenüber Dhorivirus | |
Secretion of Hepatitis C virus replication intermediates reduces activation of Toll-like receptor 3 in hepatocytes | |
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience | |
Survival prediction using the Freiburg index of post-TIPS survival (FIPS) in critically ill patients with acute- on chronic liver failure: A retrospective observational study | |
T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine | |
TCF1+ hepatitis C virus-specific CD8+ T cells are maintained after cessation of chronic antigen stimulation | |
Tetramer enrichment reveals the presence of phenotypically diverse hepatitis C virus-specific CD8+T cells in chronic infection | |
Th1-biased hepatitis C virus-specific follicular T helper-like cells effectively support B cells after antiviral therapy | |
Toward a better understanding of hepatocellular carcinoma immune infiltrates | |
TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection | |
transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression | |
transjugular intrahepatic portosystemic shunt: Smaller stent diameters are required to optimize pressure response | |
transjuguläre intrahepatische portosystemische Shunt (TIPS) in der Therapie der portalen Hypertension: Indikation, Stentauswahl, Langzeitverlauf, Komplikationen und prognostische Faktoren in einer retrospektiven monozentrischen Studie | |
Treating hepatitis D with bulevirtide – real-world experience from 114 patients | |
Tumorantigen-spezifische CD8+ T-Zellen bei Patienten mit hepatozellulaerem Karzinom | |
Unique and common features of innate-like human V[delta]2+ [gamma] [delta] T cells and mucosal-associated invariant T cells | |
Ustekinumab inhibits T follicular helper cell differentiation in patients with Crohn’s disease | |
Validation of color Doppler ultrasound and computed tomography in the radiologic assessment of non-malignant acute splanchnic vein thrombosis | |
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients | |
Zytokinmuster im Plasma von Patienten mit chronisch viraler Hepatitis |